BMRN vs. CPRX

In the year-to-date period, BMRN achieves a -3.70% return, which is significantly lower than CPRX's 12.36% return. Over the past 10 years, BMRN has underperformed CPRX with an annualized return of -5.83%, while CPRX has yielded a comparatively higher 21.69% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMRN Sharpe Ratio is -0.87, which is lower than the CPRX Sharpe Ratio of 1.43. The chart below compares the historical Sharpe Ratios of BMRN and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BMRN nor CPRX has paid dividends to shareholders.

The maximum BMRN drawdown since its inception was -90.58%, roughly equal to the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for BMRN and CPRX. For additional features, visit the drawdowns tool.

BioMarin Pharmaceutical Inc. (BMRN) has a higher volatility of 17.90% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 14.53%. This indicates that BMRN's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.